Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Maxwell Hunter as the company’s Chief Operating Officer.
“Our executive team is bolstered tremendously by the addition of Max as our new COO,” said Keegan Begley, President at Kolosis. “We keenly understand that responsiveness to our sales channel is key to our success and that it all begins with our operations support. Max brings valuable experience in building systems to support complex commercial operations and we look forward to his leadership in helping us build a scalable foundation for our planned growth.”
Prior to joining Kolosis, Maxwell served as Chief Financial Officer at Titan Mobile where he xxxxxxx. Prior to that, Maxwell was CFO at multiple large land development and residential home building companies in Salt Lake City.
“I’m thrilled to join Kolosis so early in its pathway to commercial success,” said Maxwell Hunter. “I look forward to making the company an industry leader in providing resources and support to sales partners, caregivers, and our strategic partners.”
Kolosis BIO is a pure-play orthobiologics company dedicated to commercializing Bold Technologies with Relentless Execution. Kolosis exclusively partners with MTF to deliver market-leading bone graft technologies in the orthopedic space. The company represents two MTF bone graft technologies; Kore Fiber, a 100% cortical fiber allograft, and Prime HD, a pre-hydrated DBM. Both grafts offer superior quality through MTF’s proprietary aseptic processing methods which optimally preserve matrix structures and osteoinductive properties. For more information visit www.kolosis.com.